Blinatumomab activity in a patient with Down syndrome B-precursor acute lymphoblastic leukemia.

about

Blinatumomab activity in a patient with Down syndrome B-precursor acute lymphoblastic leukemia.

Item

http://www.wikidata.org/entity/Q47786126

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Blinatumomab activity in a pat ...... acute lymphoblastic leukemia.

@en

Blinatumomab activity in a pat ...... acute lymphoblastic leukemia.

@nl

type

Item

label

Blinatumomab activity in a pat ...... acute lymphoblastic leukemia.

@en

Blinatumomab activity in a pat ...... acute lymphoblastic leukemia.

@nl

prefLabel

Blinatumomab activity in a pat ...... acute lymphoblastic leukemia.

@en

Blinatumomab activity in a pat ...... acute lymphoblastic leukemia.

@nl

P1476

Blinatumomab activity in a pat ...... r acute lymphoblastic leukemia

@en

P2093

Ana C Xavier

http://www.w3.org/2001/XMLSchema#string

P2860

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.

Risks of leukaemia and solid tumours in individuals with Down's syndrome.

Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421.

Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.

Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.

Acute lymphoblastic leukaemia in children with Down syndrome: an updated review.

Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.

P31

scholarly article

P356

10.1002/PBC.26824

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Matthew A Kutny

Aman Wadhwa

P577

2017-09-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28921818

http://www.w3.org/2001/XMLSchema#string